Effect of buspirone, a 5-HT1A receptor agonist, on esophageal motility in healthy volunteers

Diseases of the Esophagus

Volumn 25, Issue 5, 2012, Pages 470-476

  Di Stefano, M ^a,b   Papathanasopoulos, A ^a   Blondeau, K ^a   Vos, R ^a   Boecxstaens, V ^a   Farre R ^a   Rommel, N ^a   Tack, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

5 hydroxytryptamine1A receptor; Buspirone; Esophageal motility

Indexed keywords

BUSPIRONE; PLACEBO; SEROTONIN 1A RECEPTOR;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOWER ESOPHAGUS SPHINCTER; MALE; NORMAL HUMAN; PLACEBO EFFECT; PRIORITY JOURNAL; SWALLOWING;

ADULT; BUSPIRONE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGUS; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MANOMETRY; PERISTALSIS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84863433971     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01275.x     Document Type: Article

References (40)

1. Goyal R K, Chaudhury A. Physiology of normal esophageal motility. J Clin Gastroenterol 2008; 42: 610-9.
2. Smout A J. Advances in esophageal motor disorders. Curr Opin Gastroenterol 2008; 24: 485-9.
3. Sifrim D, Fornari F. Non-achalasic motor disorders of the oesophagus. Best Pract Res Clin Gastroenterol 2007; 21: 575-93.
4. Broussard D L, Wiedner E B, Li X, Altschuler S M. NMDAR1 mRNA expression in the brainstem circuit controlling esophageal peristalsis. Brain Res Mol Brain Res 1994; 27: 329-32.
5. Hornby P J, Abrahams T P. Central control of lower esophageal sphincter relaxation. Am J Med 2000; 108 (Suppl 4a): 90S-8S.
6. Barone F C, Lombardi D M, Ormsbee H S 3rd. Effects of hindbrain stimulation on lower esophageal sphincter pressure in the cat. Am J Physiol 1984; 247 (1 Pt 1): G70-8.
7. Rossiter C D, Norman W P, Jain M, Hornby P J, Benjamin S, Gillis R A. Control of lower esophageal sphincter pressure by two sites in dorsal motor nucleus of the vagus. Am J Physiol 1990; 259 (6 Pt 1): G899-906.
8. Richards W G, Sugarbaker D J. Neuronal control of esophageal function. Chest Surg Clin N Am 1995; 5: 157-71.
9. Humphries T J, Castell D O. Effect of oral bethanechol on parameters of esophageal peristalsis. Dig Dis Sci 1981; 26: 129-32.
10. Broussard D L, Li X, Altschuler S M. Localization of GABAA alpha 1 mRNA subunit in the brainstem nuclei controlling esophageal peristalsis. Brain Res Mol Brain Res 1996; 40: 143-7.
11. Tack J, Coremans G, Janssens J. A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Drug Saf 1995; 12: 384-92.
12. Staiano A, Clouse R E. The effects of cisapride on the topography of oesophageal peristalsis. Aliment Pharmacol Ther 1996; 10: 875-82.
13. Song C W, UM S H, Kim C D, Ryu H S, Hyun J H, Choe J G. Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit. Scand J Gastroenterol 1997; 32: 541-6.
14. Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003; 15: 1115-21.
15. Delvaux M, Maisin J M, Arany Y etal. The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther 1995; 9: 563-9.
16. Tutuian R, Mainie I, Allan R etal. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther 2006; 24: 155-62.
17. Fox M, Menne D, Stutz B, Fried M, Schwizer W. The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Aliment Pharmacol Ther 2006; 24: 1017-27.
18. Drolet B, Khalifa M, Daleau P, Hamelin B A, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204-10.
19. Busti A J, Murillo J R Jr, Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24: 526-31.
20. Foster J M, Houghton L A, Whorwell P J, Morris J. Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. Aliment Pharmacol Ther 1999; 13: 927-36.
21. Sifrim D, Holloway R H, Tack J, Zelter A, Missotten T, Coulie B, Janssens J. Effect of sumatriptan, a 5HT1 agonist, on the frequency of transient lower esophageal sphincter relaxations and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 1999; 94: 3158-64.
22. Coulie B, Tack J, Maes B, Geypens B, De Roo M, Janssens J. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 1997; 272: (4 Pt 1): G902-8.
23. Tack J, Coulie B, Wilmer A, Andrioli A, Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46: 468-73.
24. Van Oudenhove L, Kindt S, Vos R, Coulie B, Tack J. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008; 28: 1326-33.
25. Tack J, Coulie B, Wilmer A, Peeters T, Janssens J. Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 1998; 42: 36-41.
26. Tack J, Coulie B, Wilmer A, Vos R, Janssens J. The 5-HT1A agonist buspirone induces a premature intestinal activity front in man. Gastroenterology 1997; 112: A834.
27. Michalets E L, Williams C R. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000; 39: 49-75.
28. Koutsoumbi P, Epanomeritakis E, Tsiaoussis J etal. The effect of erythromycin on human esophageal motility is mediated by serotonin receptors. Am J Gastroenterol 2000; 95: 3388-92.
29. Tzovaras G, Xynos E, Chrysos E, Mantides A, Vassilakis J S. The effect of intravenous erythromycin on esophageal motility in healthy subjects. Am J Surg 1996; 171: 316-9.
30. Champion G, Richter J E, Singh S, Schan C, Nellans H. Effects of oral erythromycin on esophageal pH and pressure profiles inpatients with gastroesophageal reflux disease. Dig Dis Sci 1994; 39: 129-37.
31. Katapadi K, Kostandy G, Katapadi M, Hussain K M, Schifter D. A review of erythromycin-induced malignant tachyarrhythmia - torsade de pointes. A case report. Angiology 1997; 48: 821-6.
32. Di Stefano M, Vos R, Sifrim D, Tack J. Effect of buspirone, a 5HT1A agonist on esophageal peristalsis and lower esophageal sphincter function in healthy volunteers. Gastroenterology 2004; 126: A-638.
33. Pandolfino J E, Bulsiewicz W J. Evaluation of esophageal motor disorders in the era of high-resolution manometry and intraluminal impedance. Curr Gastroenterol Rep 2009; 11: 182-9.
34. Tutuian R, Castell D O. Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Clin Gastroenterol Hepatol 2004; 2: 230-6.
35. Blonski W, Vela M F, Freeman J, Sharma N, Castell D O. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J Clin Gastroenterol 2009; 43: 253-60.
36. Tack J, Demedts I, Dehondt G etal. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122: 1738-47.
37. Tack J, Janssens J, Vantrappen G, Wood J D. Actions of 5-hydroxytryptamine on myenteric neurons in guinea-pig gastric antrum. Am J Physiol 1992; 263: G838-46.
38. Rickels K. Buspirone in clinical practice. J Clin Psychiatry 1990; 51 (Suppl): 51-4.
39. Tack J. Is there a unifying role for visceral hypersensitivity and irritable bowel syndrome in non-erosive reflux disease? Digestion. 2008; 78 (Suppl 1): 42-5.
40. Drossman D A. Functional abdominal pain syndrome. Clin Gastroenterol Hepatol 2004; 2: 353-65.